Furthermore, patients receiving PD-1 or PD-L1 inhibitors that have high polygenic risk score for hypothyroidism are reported to have longer survival but also a higher risk of hypo- and hyperthyroidism as well as vitiligo39. This evidence concerns the gene CD274 and hyperthyroidism.